MedTrace Logo

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2026-05-06

No results posted yet for this study

Summary

Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Conditions

  • Ulcerative Colitis (UC)

Interventions

BIOLOGICAL

XmAb942

Antibody

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Osterman, MD, MSCE · Xencor, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-10
Primary Completion
2028-04-30
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • Croatia
  • Georgia
  • Greece
  • Hungary
  • Moldova
  • Poland
  • Romania
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06619990 on ClinicalTrials.gov